Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stok Raporu

Piyasa değeri: US$175.9m

Tenaya Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Tenaya Therapeutics CEO'su Faraz Ali, Jun2018 tarihinde atandı, in görev süresi 6.42 yıldır. in toplam yıllık tazminatı $ 2.89M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.5% maaş ve 79.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.045% ine doğrudan sahiptir ve bu hisseler $ 79.55K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 6.4 yıldır.

Anahtar bilgiler

Faraz Ali

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi20.5%
CEO görev süresi6.4yrs
CEO sahipliği0.05%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi6.4yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Sep 18
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Jun 04
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Mar 07
Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

CEO Tazminat Analizi

Faraz Ali'un ücretlendirmesi Tenaya Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$117m

Jun 30 2024n/an/a

-US$121m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$3mUS$594k

-US$124m

Sep 30 2023n/an/a

-US$128m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$6mUS$571k

-US$124m

Sep 30 2022n/an/a

-US$116m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$5mUS$494k

-US$73m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$750kUS$425k

-US$38m

Tazminat ve Piyasa: Faraz 'nin toplam tazminatı ($USD 2.89M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.47M ).

Tazminat ve Kazançlar: Faraz 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Faraz Ali (51 yo)

6.4yrs

Görev süresi

US$2,890,062

Tazminat

Mr. Faraz Ali, M.B.A., serves as Chief Executive Officer since June 2018 & Director since September 2018 at Tenaya Therapeutics, Inc. and served as its Secretary since June 2018. Mr. Ali served as Chief Bu...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Faraz Ali
CEO & Director6.4yrsUS$2.89m0.045%
$ 79.5k
Deepak Srivastava
Scientific Founderno dataUS$280.39k0.71%
$ 1.3m
Whittemore Tingley
Chief Medical Officer5.9yrsUS$1.38m0.055%
$ 96.3k
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno dataVeri yokVeri yok
Bruce Conklin
Scientific Founderno dataVeri yokVeri yok
Saptarsi Haldar
Scientific Founderno dataVeri yokVeri yok
Sheng Ding
Scientific Founderno dataVeri yokVeri yok
Benoit Bruneau
Scientific Founderno dataVeri yokVeri yok
Chihiro Saito
Senior Accounting & Financial Operations and Interim Principal Accounting Officerless than a yearVeri yok0.0069%
$ 12.1k
Kee-Hong Kim
Chief Technology Officer2.7yrsVeri yokVeri yok
Michelle Corral
Vice President of Investor Relationship & Corporate Communicationsno dataVeri yokVeri yok
Jennifer Drimmer
General Counsel & Corporate Secretary2.8yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: TNYA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Faraz Ali
CEO & Director6.4yrsUS$2.89m0.045%
$ 79.5k
Deepak Srivastava
Scientific Founder8.1yrsUS$280.39k0.71%
$ 1.3m
Eric Olson
Scientific Founder & Member of Scientific Advisory Boardno dataVeri yokVeri yok
David Goeddel
Independent Chairman of the Board8.3yrsUS$228.89kVeri yok
Mark Kay
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey Walsh
Independent Director4.7yrsUS$214.89k0%
$ 0
Douglas Mann
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Timothy Hoey
Member of Scientific Advisory Boardless than a yearUS$2.56m0.25%
$ 433.7k
R. Williams
Independent Director8.1yrsUS$207.39k0.038%
$ 66.6k
Jonathan Weissman
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Elizabeth McNally
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Catherine Stehman-Breen
Independent Director4.4yrsUS$202.39k0.010%
$ 18.0k

6.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TNYA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).